2-[(3-chloro-pyridin-2-yl)methylthio]ethylamine | 71351-66-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[(3-chloro-pyridin-2-yl)methylthio]ethylamine
• 英文别名: 3-chloro-2-((2-aminoethyl)thiomethyl)-pyridine；3-chloro-2-((2-aminoethyl)thiomethyl) pyridine；2-[(2-aminoethyl)thiomethyl]-3-chloropyridine；3-chloro-2-[(2-aminoethyl)thiomethyl]pyridine；2-((3-chloro-2-pyridyl)methylthio)ethylamine；2-[(3-chloro-2-pyridyl)methylthio]ethylamine；2-(3-Chloropyrid-2-ylmethylthio)ethylamine；2-[(3-chloropyridin-2-yl)methylsulfanyl]ethanamine
• CAS: 71351-66-1
• 化学式: C₈H₁₁ClN₂S
• 分子量: 202.708
• InChiKey: HTABEAIBEITBJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(3-chloro-pyridin-2-yl)methylthio]ethylamine 生成 1-Nitro-2-[2-((3-chloro-pyridin-2-yl)methylthio)ethylamino]-2-[2-((2-amino-4-imidazolyl)methylthio)ethylamino]ethylene
  参考文献：
  名称：

  Pyridyl-alkylaminoethylene compounds

  摘要：

  这些化合物是乙烯衍生物，是组胺活性的抑制剂，特别是H-2组胺受体的抑制剂。本发明的一种化合物是1-硝基-2-[2-((4-甲基-5-咪唑基)甲硫基)乙基氨基]-2-[2-((3-氯-2-吡啶基)甲硫基)乙基氨基]乙烯。

  公开号：

  US04013769A1

文献信息

• Pyridyl alkylguanidine compounds, composition therewith, and methods of
  申请人：Smith Kline & French Laboratories Limited

  公开号：US03971786A1

  公开（公告）日：1976-07-27

  The compounds are pyridyl alkylguanidines, for example N-benzenesulphonyl-N'-methyl-N"-[2-((3-hydroxy-2-pyridyl)methylthio)ethyl] guanidine, which are inhibitors of histamine activity.

  这些化合物是吡啶基烷基胍，例如N-苯磺酰-N'-甲基-N"-[2-((3-羟基-2-吡啶基)甲硫基)乙基] 胍，它们是组织胺活性的抑制剂。
• Thiadiazole histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04471122A1

  公开（公告）日：1984-09-11

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组织名称为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮5-至9-成员完全饱和的杂环环；m为0到2的整数；n为2到4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其新型抗溃疡剂的无毒药用盐、水合物、溶剂合物或N-氧化物。披露了其制备的中间体和方法。
• Chemical compounds
  申请人：Bristol-Myers Company

  公开号：US04394508A1

  公开（公告）日：1983-07-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组胺H.sub.2-拮抗剂的化学结构为##STR1##，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的5至9成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性的药学可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。揭示了其中间体和制备方法。
• Histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04510309A1

  公开（公告）日：1985-04-09

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮杂环环的5到9成员完全饱和的环；m为0到2的整数，n为2到4的整数；Z为硫、氧或亚甲基；A为可选取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性药用可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。公开了其制备的中间体和方法。
• Pyridyl guanidine anti-ulcer agents
  申请人：Bristol-Myers Company

  公开号：US04250316A1

  公开（公告）日：1981-02-10

  Compounds of the formula ##STR1## wherein R.sup.1 is a straight or branched chain alkynyl group containing from 3 to 9 carbon atoms, inclusive; R.sup.2 is hydrogen, hydroxy, cyano, (lower)alkyl, (lower)alkoxy, halogen or amino; n is 2 or 3; X is NR.sup.3 or CHR.sup.3 ; R.sup.3 is cyano, nitro, SO.sub.2 Ar; or SO.sub.2 (lower)alkyl; R.sup.12 is hydrogen or (CH.sub.2).sub.p NR.sup.13 R.sup.14 ; p is an integer of from 1 to 4, inclusive; R.sup.13 and R.sup.14 each are independently hydrogen or (lower)alkyl; and Ar is phenyl or phenyl containing 1 or 2 substituents independently selected from halogen and (lower)alkyl; and nontoxic, pharmaceutically acceptable salts thereof, are potent anti-ulcer agents.

  该化合物的分子式为##STR1##其中R.sup.1是含有3到9个碳原子的直链或支链炔基团；R.sup.2是氢、羟基、氰基、(较低)烷基、(较低)烷氧基、卤素或氨基；n为2或3；X为NR.sup.3或CHR.sup.3；R.sup.3为氰基、硝基、SO.sub.2 Ar；或SO.sub.2(较低)烷基；R.sup.12为氢或(CH.sub.2).sub.p NR.sup.13 R.sup.14；p为1到4的整数；R.sup.13和R.sup.14各自独立地是氢或(较低)烷基；Ar为苯或含有1或2个卤素和(较低)烷基的苯基；以及其无毒、药用可接受盐，是有效的抗溃疡药物。